Terms: = Skin cancer AND IDH1, IDP, 3417, ENSG00000138413, IDH, PICD, O75874 AND Treatment
16 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. The first-in-human phase I study of a brain-penetrant mutant idh1 inhibitor DS-1001 in patients with recurrent or progressive idh1-mutant gliomas.
Natsume A; Arakawa Y; Narita Y; Sugiyama K; Hata N; Muragaki Y; Shinojima N; Kumabe T; Saito R; Motomura K; Mineharu Y; Miyakita Y; Yamasaki F; Matsushita Y; Ichimura K; Ito K; Tachibana M; Kakurai Y; Okamoto N; Asahi T; Nishijima S; Yamaguchi T; Tsubouchi H; Nakamura H; Nishikawa R
Neuro Oncol; 2023 Feb; 25(2):326-336. PubMed ID: 35722822
[TBL] [Abstract] [Full Text] [Related]
3. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract] [Full Text] [Related]
4. idh1 inhibitor-induced neutrophilic dermatosis in a patient with acute myeloid leukemia.
Dunn-Valadez S; Bathini S; Elston C; Rangaraju S; Stasi AD; Worth S; Morlote D; Harada S; Vachhani P
Cancer Treat Res Commun; 2022; 31():100560. PubMed ID: 35460975
[TBL] [Abstract] [Full Text] [Related]
5. Tumour treating fields in glioblastoma: is the treatment tolerable, effective, and practical in UK patients?
Olubajo F; Thorpe A; Davis C; Sinha R; Crofton A; Mills SJ; Williams M; Jenkinson MD; Price SJ; Watts C; Brodbelt AR
Br J Neurosurg; 2022 Dec; 36(6):770-776. PubMed ID: 35200077
[TBL] [Abstract] [Full Text] [Related]
6. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma.
Herrera-Rios D; Li G; Khan D; Tsiampali J; Nickel AC; Aretz P; Hewera M; Suwala AK; Jiang T; Steiger HJ; Kamp MA; Muhammad S; Hänggi D; Maciaczyk J; Zhang W; Kahlert UD
Sci Rep; 2020 Oct; 10(1):16218. PubMed ID: 33004830
[TBL] [Abstract] [Full Text] [Related]
7. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
[TBL] [Abstract] [Full Text] [Related]
8. Personalized and targeted mutational analysis of multiple second primary melanomas under kinase inhibitors.
Donati M; Zelano G; Coppola R; Cinelli E; Verri M; Persichetti P; Perrella E; Devirgiliis V; Calvieri S; Crescenzi A; Panasiti V
Ital J Dermatol Venerol; 2021 Oct; 156(5):593-598. PubMed ID: 31804055
[TBL] [Abstract] [Full Text] [Related]
9. Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia.
Kubasch AS; Wehner R; Bazzurri S; Tunger A; Stasik S; Garzarolli M; Meinel J; Baretton G; Meier F; Thiede C; Schmitz M; Platzbecker U
Blood Adv; 2018 Jun; 2(11):1187-1190. PubMed ID: 29844203
[TBL] [Abstract] [Full Text] [Related]
10. Altered epigenetic pathways and cell cycle dysregulation in healthy appearing skin of patients with koebnerized squamous cell carcinomas following skin surgery.
Gambichler T; Rüddel I; Hessam S; Bechara FG; Stockfleth E; Schmitz L
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1485-1491. PubMed ID: 29478287
[TBL] [Abstract] [Full Text] [Related]
11. Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management.
Vecht C; Royer-Perron L; Houillier C; Huberfeld G
Curr Pharm Des; 2017; 23(42):6464-6487. PubMed ID: 29076421
[TBL] [Abstract] [Full Text] [Related]
12. Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.
Gutteridge RE; Singh CK; Ndiaye MA; Ahmad N
Cancer Lett; 2017 May; 394():13-21. PubMed ID: 28235541
[TBL] [Abstract] [Full Text] [Related]
13. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies.
Kunz M; Hölzel M
Cancer Metastasis Rev; 2017 Mar; 36(1):53-75. PubMed ID: 28210865
[TBL] [Abstract] [Full Text] [Related]
14. Seizures in oligodendroglial tumors.
Kerkhof M; Benit C; Duran-Pena A; Vecht CJ
CNS Oncol; 2015; 4(5):347-56. PubMed ID: 26478444
[TBL] [Abstract] [Full Text] [Related]
15. idh1, a CHOP and C/EBPβ-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis.
Yang X; Du T; Wang X; Zhang Y; Hu W; Du X; Miao L; Han C
Cancer Lett; 2015 Sep; 365(2):201-10. PubMed ID: 26049021
[TBL] [Abstract] [Full Text] [Related]
16. Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis.
Battistella M; Robert C; Gossot D; Dupuy A; Mateus C; Kérob D; Avril MF; Basset-Seguin N; Lebbé C; de Kerviler E; Viguier M
J Eur Acad Dermatol Venereol; 2012 May; 26(5):602-10. PubMed ID: 21615526
[TBL] [Abstract] [Full Text] [Related]
